Correspondence | Published:

High-dose chemotherapy and autologous stem cell transplantation in enteropathy-associated and other aggressive T-cell lymphomas: a UK NCRI/Cancer Research UK Phase II Study

  • A Correction to this article was published on 12 March 2019

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Change history

  • 06 March 2019

    In the original version of this manuscript, the mention of ‘ifosfamide 1500mg/m2 days 1-3’ should in fact read ‘ifosfamide 1500mg/m2 bd days 1-3’. This has now been updated in the original version of the manuscript.

  • 12 March 2019

    In the original version of this article, the mention of ‘ifosfamide 1500 mg/m2 days 1–3’ should, in fact, read ‘ifosfamide 1500 mg/m2 bd days 1–3’. This has now been updated in the original version of the article.

References

  1. 1.

    Kluin-Nelemans HC, van Marwijk Kooy M, Lugtenburg PJ, van Putten WL, Luten M, Oudejans J, et al. Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. Ann Oncol. 2011;22:1595–1600. https://doi.org/10.1093/annonc/mdq635

  2. 2.

    Schmitz N, Trumper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010;116:3418–25. https://doi.org/10.1182/blood-2010-02-270785

  3. 3.

    d’Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30:3093–9. https://doi.org/10.1200/JCO.2011.40.2719

  4. 4.

    Sieniawski M, Angamuthu N, Boyd K, Chasty R, Davies J, Forsyth P, et al. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood. 2010;115:3664–70. https://doi.org/10.1182/blood-2009-07-231324

  5. 5.

    Delabie J, Holte H, Vose JM, Ullrich F, Jaffe ES, Savage KJ, et al. Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project. Blood. 2011;118:148–55. https://doi.org/10.1182/blood-2011-02-335216

  6. 6.

    Gale J, Simmonds PD, Mead GM, Sweetenham JW, Wright DH. Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. J Clin Oncol. 2000;18:795–803. https://doi.org/10.1200/JCO.2000.18.4.795

  7. 7.

    Vose J, Armitage J, Weisenburger D, International TCLP. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124–30. https://doi.org/10.1200/JCO.2008.16.4558

  8. 8.

    Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86. https://doi.org/10.1200/JCO.2006.09.2403

  9. 9.

    Jantunen E, Boumendil A, Finel H, Luan JJ, Johnson P, Rambaldi A, et al. Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT. Blood. 2013;121:2529–32. https://doi.org/10.1182/blood-2012-11-466839

  10. 10.

    Yamaguchi M, Suzuki R, Oguchi M, Asano N, Amaki J, Akiba T, et al. Treatments and outcomes of patients with extranodal natural killer/t-cell lymphoma diagnosed between 2000 and 2013: A cooperative study in Japan. J Clin Oncol. 2017;35:32–9. https://doi.org/10.1200/JCO.2016.68.1619

  11. 11.

    Sieniawski M, Lennard J, Lyons S, Maung Z, Mounter P, Hervey V, et al. Long term follow-up of patients with peripheral T-cell lymphomas treated with ifosfamide, etoposide, epirubicin, intermediate methotrexate and autologous stem cell transplantation. Haematologica. 2017;102:P225 (Abstract).

  12. 12.

    Smith SM, Burns LJ, van Besien K, Lerademacher J, He W, Fenske TS, et al. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol. 2013;31:3100–9. https://doi.org/10.1200/JCO.2012.46.0188

Download references

Acknowledgements

Conduct of this study was funded by Cancer Research UK (grant reference: C12372/A4755). This trial is registered at clinicaltrials.gov (NCT00669812) and EudraCT (2005-003906-27).

Author information

Conflict of interest

The authors declare that they have no conflict of interest.

Correspondence to Elizabeth H. Phillips.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark
Fig. 1